AU2001277078A1 - Adult human dental pulp stem cells in vitro and in vivo - Google Patents
Adult human dental pulp stem cells in vitro and in vivoInfo
- Publication number
- AU2001277078A1 AU2001277078A1 AU2001277078A AU2001277078A AU2001277078A1 AU 2001277078 A1 AU2001277078 A1 AU 2001277078A1 AU 2001277078 A AU2001277078 A AU 2001277078A AU 2001277078 A AU2001277078 A AU 2001277078A AU 2001277078 A1 AU2001277078 A1 AU 2001277078A1
- Authority
- AU
- Australia
- Prior art keywords
- cell
- dentin
- cells
- human
- pulp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
ADULT HUMAN DENTAL PULP STEM CELLS IN VITRO AND IN VIVO
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates to the field of restorative dentistry in humans. Specifically, the present invention relates to a population of cells that can differentiate into dentin/pulp and a method of regenerating dentin/pulp.
BACKGROUND ART
During tooth formation, interactions between epithelial and dental papilla cells promote tooth morphogenesis by stimulating a subpopulation of mesenchymal cells to differentiate into odontoblasts, which in turn form primary dentin. Morphologically, odontoblasts are columnar, polarized cells with eccentric nuclei and long cellular processes aligned at the outer edges of dentin (1). Following tooth eruption, secondary dentin is formed by odontoblasts in response to general mechanical erosion or disruption, and through dentinal degradation caused by bacteria (2). These odontoblasts are thought to arise from the proliferation and differentiation of a precursor population, residing somewhere within the pulp tissue (3). Despite extensive knowledge of tooth development, and of the various specialized tooth-associated cell types, little is known about the characteristics and properties of their respective precursor cell populations in the post-natal organism.
Dentinal repair in the post-natal organism occurs through the activity of specialized cells, odontoblasts, that are thought to be maintained by an as yet undefined precursor population associated with pulp tissue (1). To date, the identification and
isolation of an odontogenic progenitor population from adult dental pulp tissue has never been performed. It is known that in certain conditions, cultures of pulp cells derived from early developing dental root tissue and pulp tissue can develop an odontoblast-like appearance with the capacity to form mineralized nodules in vitro (4) a trait normally attributed to cultures of bone or bone marrow cells (5, 6). More is known about the characteristics of multipotent bone marrow stromal cells (BMSCs) and their potential to develop into osteoblasts, chondrocytes, adipocytes, myelosupportive fibrous-stroma, and perhaps even muscle and neural tissues (7-12). They are characterized by their high prohferative capacity ex vivo, while maintaining their ability to differentiate into multiple stromal cell lineages.
Because the prior art does not provide for regenerating dentin pulp tissue or producing a human tooth for restorative purposes, there exists a great need to find a means for producing tissue that can differentiate into a functional tooth. In this study, a clonogenic, rapidly prohferative population of cells from adult human dental pulp was isolated. These dental pulp stem cells (DPSCs) were then compared to human bone marrow stromal cells (BMSCs), known precursors of osteoblasts. Although they share a similar immunophenotype in vitro, functional studies showed that DPSCs produced only sporadic, but densely calcified nodules, and did not form adipocytes, whereas BMSCs routinely calcified throughout the adherent cell layer with clusters of lipid- laden adipocytes. When DPSCs were transplanted into immunocompromised mice, they generated a dentin-like structure lined with human odontoblast-like cells that surrounded a pulp-like interstitial tissue. In contrast, BMSCs formed lamellar bone containing osteocytes and surface lining osteoblasts, surrounding a fibrous vascular tissue with active hematopoiesis and adipocytes. This study is the first to isolate postnatal human dental pulp stem cells that have the ability to form a dentin/pulp complex.
The present invention overcomes the previous limitations and shortcomings in the art by providing a human adult dental pulp stem cell (DPSC) that can differentiate into dentin/pulp tissue and a method for regenerating dentin/pulp and for producing a human tooth.
SUMMARY OF THE INVENTION
The present invention provides a culture of isolated adult human dental pulp stem cells.
The present invention also provides a method of regenerating human dentin/pulp tissue, comprising a) contacting a cell from a culture of isolated adult human dental pulp stem cells with hydiOxyapatite/tricalcium phosphate and b) transplanting the cell from step a) into a mammal.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1A-1E. Colony forming efficiency and cell proliferation in vitro.
Representative high (A) and low (B) density colonies after 14 days. The morphology is typical of fibroblast-like cells (C). The incidence of colony forming cells from dental- pulp tissue and bone marrow at various plating densities indicates that there are more clonogenic cells in dental pulp than in bone marrow (D). The number of BrdU positive cells was expressed as a percentage of the total number of cells counted for DPSCs and BMSCs (E). Statistical significance (*) was determined using the student t-test (p≥ 0.05).
Figures 2A-2L. Immunophenotype of cultured DPSCs. Studies based on immunoperoxidase reactivity were performed on first passage cultures of DPSCs. Representative staining patterns are shown for: integrin βl, (A); CD44, (B); collagen type I, (C); collagen type III, (D); FGF-2, (E); osteonectin, (F); osteocalcin, (G); MUC- 18, (H); -smooth muscle actin, (I); osteopontin, (J); VCAM-1, (K). Endogenous, alkaline phosphatase activity is shown in (L).
Figures 3A-3D. Developmental potential in vitro. Adherent layers of cultured DPSCs (A & B), and BMSCs (C & D), are shown with Alizarin Red staining as a measure of calcium accumulation following 6 weeks of induction with L-ascorbate-2- phosphate and dexamethasone with inorganic phosphate (A & C). After 6 weeks in the same medium but without inorganic phosphate, lipid accumulation was noted in BMSCs (D), but not in DPSCs (B).
Figures 4A-4F. Developmental potential in vivo. Cross sections are representative of DPSC transplants, (A, C, D) and BMSC transplants, (B, E, F) 6 weeks post-transplantation and stained with hematoxylin and eosin. In the DPSC transplants, the HA/TCP carrier surfaces (c) are lined with a dentin-like matrix (d), surrounding a pulp-like tissue with blood vessels (bv) and an interface layer of odontoblast-like cells (od) (A). A magnified view of the dentin matrix (d) highlights the odontoblast-like layer (od) and odontoblast processes (arrow) (C). Polarized light demonstrates perpendicular alignment (dashed lines) of the collagen fibers to the forming surface (D). In BMSC transplants, lamellar bone (b) is formed on the HA/TCP surfaces (c) and surrounds a vascular, hematopoietic marrow organ (hp) with accumulated adipocytes (a) (B). A magnified view shows that the new bone contains osteocytes (oc), embedded within the calcified matrix, and osteoblasts (ob) lining the bone surfaces (E). With polarized light, collagen fibrils are seen to be deposited parallel with the forming surface (dashed lines) (F).
Figures 5A-5B. In situ hybridization for the human specific alu DNA sequence. Alu positive cells in the pulp tissue (large arrow) and odontoblast-like layer (small arrow) adjacent to the dentin matrix (d) are easily recognized in 6 week DPSC transplants (A). Osteocytes encased in the new bone matrix (small arrow) and the osteoblasts lining the bone (b) surfaces (large arrow) show positive reactivity with the alu probe in the BMSC transplants (B). Hematopoietic elements (hp) in the marrowlike organ fail to show reactivity with the alu probe.
Figures 6A-6C. Expression of the human specific Dentin Sialophosphoprotein (DSPP), osteocalcin (OC), bone sialoprotein (BSP) mRNA in DPSC transplants. Transcripts for DSPP, BSP, OC and GAPDH were detected by RT-PCR using total RNA isolated from 6 week old DSPC transplants (A). DSPP positive cells were also found in the pulp tissue and odontoblast layer (arrow) adjacent to the dentin matrix (d) by in situ hybridization (B). Specificity of the probe was verified by hybridization in the odontoblast layer (arrow) of human dental pulp (p) tissue (C). No reactivity of the DSPP specific probe was detected in human bone, bone marrow and muscle tissue.
Figures 7 A-7D. hmriunohistochemical staining of human DSPP. Bone and associated marrow elements were negative for DSPP antibody staining in BMSC transplants (A). Newly formed dentin was positive for DSPP antibody staining in DPSC transplants (arrow, B). Normal human dentin and odontoblasts in human pulp were positive for DSPP (C and D, respectively).
Figures 8A-8B. Dentin formation in DPSC transplants. Trichrome (blue) staining of dentin (arrow) in eight week old human DPSC transplants (A). Transverse section of a normal tooth depicting trichrome staining (arrow) of dentin in situ (B).
DETAILED DESCRIPTION OF THE INVENTION
As used herein, "a," "an" or "the" may mean one or more. For example, "a" cell may mean one or more cells. Moreover, "the" cell may mean one or more than one cell.
The present invention provides a culture of isolated adult human dental pulp stem cells. Adult human dental pulp stem cells can be isolated from any human permanent tooth. Alternatively, the dental pulp stem cells of the invention can be isolated from a human subject at least about 18 years of age. "Isolated" as used herein means the cell of this invention is sufficiently free of contaminants or other cell types with which the cell of the present invention is naturally found. Moreover, the isolated cell of the present invention is present in such concentration as to be the only significant cell in the sample. "Isolated" does not require that the preparation be teclmically pure (homogeneous), but it is sufficiently pure to provide the cell in a form in which it can be used therapeutically or for research.
A "stem" cell is a cell that is multipotential, clonogenic, highly prohferative and capable of regenerating tissue. Thus, a stem cell has the ability to either influence other cells in its microenvironment to differentiate into a specific cell line or can itself differentiate into another cell type that has a specific function. Thus, an adult human dental pulp stem cell of the present invention is a cell obtained from the pulp tissue of a tooth from an adult human being. The stem cell of the present invention can differentiate into a more mature and functional cell, for example an odontoblast. An odontoblast is a cell found in the oral cavity of a mammal that produces dentin, a tissue that comprises and envelops a fibrovascular pulp and is covered by an outer enamel layer of a fully-formed tooth. The dental pulp stem cell of the present invention can
produce a dentin/pulp tissue structure in vivo and in vitro. This structure is exemplified in Figure 1.
The present invention provides a stem cell that is not adipogenic. Thus, the DPSC of the present invention does not differentiate into a fat cell. Moreover, the stem cell of the present invention does not produce bone sialoprotein. Thus, the stem cell of the present invention is not a bone marrow stem cell, a cell which can differentiate into a fat cell and produces bone sialoprotein. However, the stem cell of the present invention does produce odontoblast-specific dentin sialoprotein and dentin phosphoprotein, each protein encoded by the odontoblast-specific gene known as dentin sialophosphoprotein (DSPP).
The present invention provides a method of regenerating human dentin/pulp tissue, comprising a) contacting a cell from a culture of isolated adult human DPSCs with a mineral source and b) transplanting the cell from step a) into a mammal. The stem cell of the present method is mixed with a mineral source, for example, hydroxyapatite/tricalcium phosphate. This cell/mineral composition can then be transplanted into a mammal by methods known to a person of skill in the art. The stem cell/mineral composition can be transplanted into an immunocompromised mammal, for example a mouse, wherein the transplanted tissue can produce human dentin/pulp tissue that can be harvested for transplantation into a human being. The mammal may be a mouse, sheep, cow or any mammal used for transplantation studies and known to a person of skill in the art, including a human. Further, a human recipient of the stem cell/mineral composition can be an intermediate host from whom the dentin/pulp tissue can be harvested for further transplantation into another human dental patient.
Alternatively, the human recipient of the stem cell/mineral composition can be both the donor and only recipient of the transplanted tissue.
Moreover, the present invention provides a method of producing human dentin/pulp tissue, comprising a) contacting a cell from a culture of isolated adult human DPSCs with a mineral source and b) transplanting the cell from step a) into a mammal. The stem cell of the present invention can be mixed with a mineral source, for example hydroxyapatite/tricalcium phosphate.
A person of skill in the art can transplant the stem cell/mineral composition into various sites of a mammal including subcutaneous tissue and oral tissue. It is contemplated that a person of skill in the art can transplant the stem cell/mineral composition into a tooth socket and, thereby, produce a dentin/pulp tissue in a human patient.
Moreover, the transplanted stem cell/mineral composition can be transplanted with or contacted in vitro with ameloblasts, cells that produce enamel, to produce a fully-formed functional tooth, comprising dentin/pulp tissue covered by enamel. Similarly, artificial crowns made from bio-compatible materials that mimic the hard enamel layer of teeth can be produced and used as a template. The transplanted stem cell/mineral composition can be transplanted directly into the cavity of an artificial crown where the cells can differentiate into dentin/pulp tissue in vivo, thereby forming a functional tooth.
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compositions and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. The present invention is more particularly described in the following
examples which are intended as illustrative only since numerous modifications and variations therein will be apparent to those skilled in the art.
EXAMPLES
Subjects and cell culture.
Normal human impacted third molars were collected from adults (19-29 years of age) at the Dental Clinic of the National Institute of Dental & Craniofacial Research under approved guidelines set by the NTH Office of Human Subjects Research. Tooth surfaces were cleaned and cut around the cementum-enainel junction using sterilized dental fissure burs to reveal the pulp chamber. The pulp tissue was gently separated from the crown and root and then digested in a solution of 3 mg/ml collagenase type I (Worthington Biochem, Freehold, NJ) and 4 mg/ml dispase (Boehringer Mannheim, GMBH, Germany) for one hour at 37°C. Single cell suspensions were obtained by passing the cells through a 70 μm strainer (Falcon, BD Labware, Franklin Lakes, NJ). Bone marrow cells, processed from marrow aspirates of normal human adult volunteers (20-35 years of age), were purchased from Poietic Technologies, Gaithersburg, Maryland, and then washed in growth medium. Single cell suspensions (0.01 to 1 x 1 OVwell) of dental pulp and bone marrow were seeded into 6-well plates (Costar, Cambridge, MA) with alpha Modification of Eagle's Medium (GIBCO BRL, Grand Island, NY) supplemented with 20% fetal calf serum (Equitech-Bio Inc, Kerrville, TX), 100 μM L-ascorbic acid 2-phosphate (WAKO, Tokyo, Japan), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Biofluids Inc, Rockville, MD), then incubated at 37°C in 5% CO2. To assess colony-forming efficiency, day 14 cultures were fixed with 4% formalin, and then stained with 0.1% toluidine blue. Aggregates of ≥50 cells were scored as colonies. Conditions for the induction of calcified bone matrix deposition in vitro were as reported previously (6). The proliferation rate of
sub-confluent cultures (first passage) of DPSCs and BMSCs was assessed by bromodeoxyuridine (BrdU) incorporation for 24 hours, using a Zymed Laboratories BrdU staining Kit (Vector Laboratories, Burlingame CA).
Immunohistochemistry.
Primary DPSCs and BMSCs were sub-cultured into 8-chamber slides (2 x 104 cells/well) (NUNC Inc, Naperville, IL). The cells were fixed in 4% formalin, and then reacted with saturating levels of primary antibodies and the corresponding control antibodies using a Zymed broad spectrum immunoperoxidase kit (Vector Laboratories). Antibodies used were: Mouse (IgG) control (Caltag, Burlingame, CA). Rabbit (Ig) control, TUK4 (anti-CD 14), QBEND 10 (anti-CD34), 2B11/PD7 (anti-CD45), M318 (anti-MyoD), 1A4 (anti- smooth muscle actin), 2F11 (anti-neurofilament), (Dako, Carpinteria, CA); H9H11 (anti-CD44), 6G10 (anti-VCAM-1) (Dr. P.J. Simmons, HCCR, Adelaide, South Australia); CC9 (anti-MUC-18) (Dr. S. Gronthos NIDCR/ NIH, MD); MAB1343 (anti-COL III), MAB1959 (anti-βl) (Chemicon, Temecula, CA); LF67 (anti-COL I), LF32 (anti-OC), BON-1 (anti-ON), LF100 (anti-BSP), LF123 (anti- OP) (Dr. L. Fisher, NIDCR/ NIH, MD); MAB1104 (anti-COL II) (RDI, Flanders, NJ); E-8 (anti-PPARγ), 147 (anti-FGF-2), (Santa Cruz, Santa Cruz, CA). Working dilutions of rabbit serum (1/500), monoclonal supematants (1/4) and purified antibodies (10 μg/ml) were used.
Histochemistry.
Secondary DPSC and BMSC cultures were washed in PBS and then fixed with 4% formalin. Alkaline phosphatase activity was assessed using a Sigma in vitro alkaline phosphatase substrate kit (85L-2). Calcium deposits were detected by treatment with 2% Alizarin Red S (pH 4.2).
Transplantation.
Approximately 5.0 xlO of DPSCs and BMSCs (third passage) were mixed with 40 mg of hydroxyapatite/tricalcium phosphate (HA/TCP) ceramic powder (Zimmer Inc, Warsaw, IN) and then transplanted subcutaneously into the dorsal surface of 10-week-old immunocompromised beige mice (NIH-bg-nu-xid, Harlan Sprague Dawley, Indianapolis, IN) as previously described (9). These procedures were performed in accordance to specifications of an approved small animal protocol (NIDCR #97-024). The transplants were recovered at 6 weeks post-transplantation, fixed with 4% formalin, decalcified with buffered 10% EDTA (pH 8.0), and then embedding in paraffin. Sections (5 m) were deparaffmized and stained with H&E.
RT-PCR.
Total RNA was prepared from collagenase/dispase digested cell suspensions of six week old DPSC transplants, using RNA STAT-60 (TEL-TEST Inc. Friendswood, TX). First-strand cDNA synthesis was performed using a first-strand cDNA synthesis kit (GIBCO BRL, Life Technologies) using an oligo-dT primer. First strand cDNA (2 μl) was diluted in a 50 μl PCR reaction of IX PCR reaction buffer: 1.5 niM MgCi2, 200 mM each dNTP, 0.2 units of AmpliTaq DNA Polymerase (Perkin-Elmer Inc, Norwalk, CT) and 10 pMol of each human specific primer sets: BSP (sense (SEQ ID NO.:l) 5'-CTATGGAGAGGACGCCACGCCTGG-3' (S(antisense, (SEQ ID NO.:2) 5'- CATAGCCATCGTAGCCTTGTCCT-3'), OC (sense, (SEQ ID NO.:3) 5'- CATGAGAGCCCTCACA-3'; antisense, (SEQ ID NO.:4) 5'- AGAGCGACACCCTAGAC-3'), DSPP (sense (SEQ ID NO.:5) 5'- GGCAGTGACTCAAAAGGAGC-3'; antisense, 5'-(SEQ ID NO.:6) TGCTGTCACTGTCACTGCTG-3 '), GAPDH (sense, (SEQ ID NO. :7) 5 ' - AGCCGCATCTTCTTTTGCGTC-3'; antisense (SEQ ID NO.:8) 5'- TCATATTTGGCAGGTTTTTCT-3'). The reactions were incubated in a PCR Express Hybaid thermal cycler (Hybaid, Franklin, MA) at 94°C for 2 minutes for 1 cycle then
94°C/(45 sec), 56°C/(45 sec), 72°C/(60 sec) for 35 cycles, with a final 10 minute extension at 72 °C. Following amplification, 10 μl of each reaction was analyzed by 1.5%) agarose gel electrophoresis, and visualized by ethidium bromide staining.
In situ hybridization.
A digoxigenin-labeled probe for human specific alu repetitive sequence was prepared by PCR using primers for alu as previously described (13). Similarly, a digoxigenin-labeled probe specific for human DSPP mRNA was also prepared using the DSPP primers under the same PCR conditions as described above. The specificity of both probes was verified by DNA sequencing. Unstained sections were deparaffinized and hybridized with either the digoxigenin-labeled alu probe (9) or the DSPP probe using the mRNAlocator-Hyb Kit (Cat # 1800; Ambion, Inc., Austin TX). After hybridization, the presence of both alu and DSPP mRNA in tissue sections was detected by immunoreactivity with an anti-digoxigenin alkaline phosphatase conjugated Fab fragments (Boehringer Mannheim).
Isolation of clonogenic populations of DPSCs.
Osteoprogenitors can be isolated from aspirates of bone marrow by their ability to adhere to a plastic substratum, and with appropriate stimulation, begin to proliferate (13-15). Each colony originates from a single progenitor cell (colony forming unit- fibroblast, CFU-F) and displays a wide variation in cell morphology and growth potential (13-18). Herein, the presence of a clonogenic cell population in dental pulp tissue (Fig. 1 A and B) is demonstrated for the first time. The cells within each colony were characterized by a typical fibroblast-like morphology (Fig. 1C) analogous to the progeny of human bone marrow CFU-F (19). The frequency of colony forming cells derived from dental pulp tissue (range 22 to 70 colonies per 104 cells plated) was significantly higher in comparison to the incidence of bone marrow CFU-F (range 2.4 to 3.1 colonies/ 104 cells plated) over similar plating densities (0.1 to 2.5 x 104 cells
plated) (Fig. ID). In addition, the number of proliferating cells in DPSC cultures was also significantly higher (mean 72% BrdU positive cells ± 3.48 SEM, n=3) when compared to BMSC cultures (46% BrdU positive cells ± 1.96 SEM, n=3) using the BrdU uptake method (t-test p< 0.05) (Fig. IE).
Characterization of the immunophenotype of DPSCs in vitro.
Immunohistochemical studies were performed to characterize the progeny of the DPSC and BMSC clonogenic populations, using a large panel of antibodies specific to known antigens associated with different phenotypes. Typical immunoreactivity profiles for both cell populations are shown in Table 1. Primary cultures of DPSC and BMSC failed to react with the hematopoietic markers CD 14 (monocyte/ macrophage), CD45 (common leukocyte antigen), CD34 (hematopoietic stem/progenitor cells/endothelium) and other markers such as MyoD (smooth muscle), neurofilament (nerve), collagen type II (cartilage) and PPARγ (fat). In general, DPSCs and BMSCs exhibited a similar expression pattern for a variety of markers associated with endothelium'(VCAM-l and MUC-18), smooth muscle (α-smooth muscle actin), bone (alkaline phosphatase, type I collagen, osteonectin, osteopontin, osteocalcin) and fibroblasts (type III collagen, FGF-2). The bone matrix protein, bone sialoprotein, was absent in DPSC cultures, but present at low levels in BMSC cultures. Representative immunoreactivity patterns for DPSC are shown in (Fig. 2). Many of the markers were not uniformly expressed, but found in subsets of cells, indicating that the DSPC population is heterogeneous, as has been shown for the BMSC population.
Differentiation potential of DPSCs in vitro. Long-term cultures (5 to 6 weeks) of DPSCs grown in the presence of L- ascorbate-2-phosphate, the glucocorticoid, dexamethasone, and inorganic phosphate demonstrated the capacity to form Alizirin Red positive condensed, nodules with high levels of calcium (Fig. 3 A). The deposits were sparsely scattered throughout the
adherent layer as single mineralized zones. In contrast, BMSC cultures produced extensive sheets of calcified deposits over the entire adherent layer following 3 to 4 weeks of induction (Fig. 3C). After 6 weeks of stimulation with dexamethasone, there was no evidence of adipogenesis in primary DPSC cultures (Fig. 3C) where as clusters of lipid-containing adipocytes were detected in primary cultures of BMSC as early as two weeks (Fig. 3D).
Ex vivo expanded DPSCs can generate a dentin/pulp structure in vivo. Because complete developmental potential and formation of an appropriate histological structure often can not be fully realized in vitro, DPSCs were transplanted in conjunction with hydroxyapatite/tricalcium phosphate (HA/TCP) powder into immunocompromised mice. After 6 weeks post-transplantation, DPSCs generated a dentin-like structure lining the surfaces of the HA/TCP particles, comprised of a highly ordered collagenous matrix deposited perpendicular to the odontoblast-like layer when viewed by polarized light (Fig. 4A, C, D). Immunological studies demonstrated that the matrix was predominantly composed of collagen type I. The odontoblast-like cells extended cytoplasmic processes into the dentinal matrix, which interfaced with a pulp-like interstitial tissue infiltrated with blood vessels. The pulp and odontoblast-like cells were found to be of donor origin based on their reactivity to the human alu specific ' probe (Fig. 5A). Furthermore, the DPSC transplants expressed human specific transcripts for dentin matrix components, including bone sialoprotein, osteocalcin and dentin sialophosphoprotein (DSPP) by RT-PCR and in situ hybridization (Fig. 6). The corresponding BMSC transplants formed distinct lamellae of bone on the surface of the HA/TCP where the collagen fibers were aligned parallel to the osteoblasts on the bone forming surfaces (Fig. 4B, E, F). Osteocytes, entombed within the bone matrix, and osteoblasts were also found to be of donor origin (Fig. 5B). Newly formed bone surrounded an interstitial tissue that was infiltrated by a sinusoid network resembling a marrow-like organ, with extensive areas of active hematopoiesis and adipocyte
accumulation. Interestingly, the DPSC transplants failed to support any hematopoiesis or to initiate adipocyte formation even 4 months post transplantation.
Immunohistochemical staining for human DSPP. Transplantation of DPSCs and BMSCs was performed as described above. The transplants were recovered 8 weeks post-transplantation and fixed for 24 hours with 4% freshly prepared paraformadehyde, and decalcified for 7 days with 10%) EDTA (pH 8.0). The transplants were then transferred to 70%> ethanol and embedded into paraffin block. The DSPP antibody was from Dr. Larry Fisher (NIDCR/NIH). After deparaffinization, rehydration, and elimination of endogenous peroxidase, the sections were incubated with the DSPP primary antibody at room temperature for 1 hour. Then Histostain SP Kits were used for second antibodies and enzyme conjugate incubation according to the instruction (Zymed Laboratories Inc. South San Francisco, CA, USA). Human pulp and demineralized dentin tissues were used as positive controls. This procedure showed that newly formed dentin in DPSCs transplants is positive for dentin specific DSPP antibody (Fig. 7). This is additional evidence that human DPSCs differentiate into odontoblasts to regenerate human dentin in vivo.
Trichrome staining of dentin formation in DPSC transplants. Transplantation of DPSCs and BMSCs was performed as described above.
Eight week old human DPSC transplants were fixed for 24 hours with 4% freshly prepared paraformalde yde, and transferred into 70% ethanol and plastic embedded. The Trichrome staining (GOMORI) kit (Sigma, #HT10516) was used for the staining according to the manufacturer's protocol. Normal tooth plastic-embedded sections were used as positive controls. This staining showed that DPSCs regenerate dentin comprising similar mineralized collagen structure as normal human dentin (Fig. 8).
The data presented here demonstrate for the first time that post-natal dental pulp contains cells that are clonogenic, highly prohferative and capable of regenerating a tissue, properties that effectively define them as stem cells. Although muscle, nervous tissue, and dentin-associated tissue do not remodel during post-natal life, they all contain stem cells that have the ability to differentiate in response to injury. The transplantation of human DPSCs into immunocompromised mice provides a new model by which to further characterize these stem cells. Furthermore, the amount of dentin and pulp-like tissue formed in these transplants far exceeds the amount that would be generated in situ during the lifetime of an organism. Consequently, the ' present isolation of a large number of DPSCs from a single tooth allows for dentinal repair of a number of teeth. Further, through the use of carriers with appropriate shape and composition in conjunction with ex vivo expanded DPSCs, the fabrication of a viable dental implant is provided.
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
References
1. Smith, A. J., Cassidy, N., Perry, H., Begue-Kirn, C, Ruch, J. V. & Lesot, H. (1995) hit JDev Biol 39, 273-80.
2. Kitamura, C, Kimura, K., Nakayama, T. & Terashita, M. (1999) JDent Res 78, 673-80.
3. Ruch, J. V. (1998) Biochem Cell Biol 76, 923-38.
4. Couble, M. L., Farges, J. C, Bleicher, F., Perrat-Mabillon, B., BoudeuUe, M. & Magloire, H. (2000) Calcif Tissue Int 66, 129-38.
5. Cheng, S. L., Yang, J. W., Rifas, L., Zhang, S. F. & Avioli, L. V. (1994) Endocrinology 134, 277-86.
6. Gronthos, S., Graves, S. E., Ohta, S. & Simmons, P. J. (1994) Blood 84, 4164- 73.
7. Friedenstein, A. J., Ivanov-Smolenski, A. A., Chajlakjan, R. K., Gorskaya, U. F., Kuralesova, A. L, Latzinik, N. W. & Gerasimow, U. W. (1978) Exp Hematol 6, 440- 4.
8. Bennett, J. H., Joyner, C. J., Triffitt, J. T. & Owen, M. E. (1991) J Cell Sci 99, 131-9.
9. Kuznetsov, S. A., Krebsbach, P. H., Satomura, K., Kerr, J., Rimfnucci, M., Benayahu, D. & Robey, P. G. (1997) J Bone Miner Res 12, 1335-47.
10. Ferrari, G., Cusella-De Angelis, G., Coletta, M., Paolucci, E., Stornaiuolo, A., Cossu, G. & Mavilio, F. (1998) Science 279, 1528-30.
11. Azizi, S. A. & et al. (1998) Proc Natl Acad Sci USA. 95, 3908-13.
12. Pittenger, M. F., Mackay, A. M., Beck, S. C, Jaiswal, R. K, Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S. & Marshak, D. R. (1999) Science 284, 143-7.
13. Bianco, P. & Robey, P. G. (2000) J. Clin. Invest. 105.
14. Robey, P. G. (2000) J Clin Invest 105, 1489-91.
15. Nakashima, M., Nagasawa, H., Yamada, Y. & Reddi, A. H. (1994) Dev Biol 162, 18-28.
16. Shiba, H., Fujita, T., Doi, N., Nakamura, S., Nakanishi, K., Takemoto, T., Hino, T., Noshiro, M., Kawamoto, T., Kurihara, H. & Kato, Y. (1998) J Cell Physiol 174, 194-205.
17. Onishi, T., Kinoshita, S., Shintani, S., Sobue, S. & Ooshima, T. (1999) Arch Oral Biol 44, 361-71.
18. Kettunen, P., Karavanova, I. & Thesleff, I. (1998) Dev Genet 22, 374-85.
19. Kuo, M. Y., Lan, W. H., Lin, S. K, Tsai, K. S. & Hahn, L. J. (1992) Arch Oral Biol 37, 945-52.
20. Tsukamoto, Y., Fukutani, S., Shin-Ike, T., Kubota, T., Sato, S., Suzuki, Y. & Mori, M. (1992) Arch Oral Biol 37, 1045-55.
21. Buurma, B., Gu, K. & Rutherford, R. B. (1999) Eur J Oral Sci 107, 282-9.
22. Ritchie, H. H., Hou, H., Veis, A. & Butler, W. T. (1994) JBiol Chem 269, 3698-702.
23. Gorter de Vries, I., Quartier, E., Van Steirteghem, A., Boute, P., Coomans, D. & Wisse, E. (1986) Arch Oral Biol 31, 57-66.
24. MacDougaU, M., Simmons, D., Luan, X., Nydegger, J., Feng, J. & Gu, T. T. (1991) JBiol Chem 272, 835-42.
25. Feng, J. Q., Luan, X., Wallace, j., ing, D., Ohshima, T., Kulkarni, A. B., D'Souza, R. N., Kozak, C. A. & MacDougaU, M. (1998) JBiol Chem 273, 9457-64.
26. Owen, M. E. (1998) (Combridge University Press, Cambridge), pp. 1-9.
27. Friedenstein, A. J. (1980) in Immunology of Bone Marrow Transplantation (Springer-Verlag, Berlin), pp. 19-29.
28. Bianco, P. & Cossu, G. (1999) Exp Cell Res 251, 257-63.
29. Bianco, P. & Riminucci, M. (1998) in Marrow stromal cell culture, eds. Owen, M. A. & Beresford, j. N. (Cambridge University Press, Cambridge UK), pp. 10-25.
30. Doherty, M. J., Ashton, B. A., Walsh, S., Beresford, J. N., Grant, M. E. & Canfield, A. E. (1998) J Bone Miner Res 13, 828-38.
31. Shiba, H., Nakamura, S., Shirakawa, M., Nakanishi, K, Okamoto, H., Satakeda, H., Noshiro, M., Kamihagi, K., Katayama, M. & Kato, Y. (1995) Dev Biol 170, 457-66.
32. Majors, A. K, Boehm, C. A., Nifto, H., Midura, R. J. & Muschler, G. F. (1997) JOrthop Res. 15, 546-57.
33. Ishizeki, K, Nawa, T. & Sugawara, M. (1990) Anat Rec 226, 279-87.
34. Holtgrave, E. A. & Donath, K. (1995) Biomaterials 16, 155-9.
35. Lyaruu, D. M., van Croonenburg, E. J., van Duin, M. A., Bervoets, T. J., Woltgens, J. H. & de Blieck-Hogervorst, J. M. (1999) J Oral Pathol Med 2%, 293-6.
36. Prime, S. S., Sim, F. R. & Reade, P. C. (1982) Transplantation 33, 561-2.
37. Schultz, E. & McCormick, K. M. (1994) Rev. Physiol. Biochem. Pharmacol. 123, 213-257.
38. Johansson, C. B., Svensson, M., Wallstedt, L., Janson, A. M. & Frisen, J. (1999) Exp Cell Res 253, 733-6.
39. Doetsch, F., Caille, I., Lim, D. A., Garcia- Verdugo, J. M. & Alvarez-Buylla, A. (1999) Cell 97, 703-16.
Table 1. Immunohistochemical analysis of human DPSCs and BMSCs in vitro.
Marker DPSC-1 DPSC-2 BMS(
CD14 - - -
CD34 - - -
CD44 ++ ++ ++
CD45 - - -
Integrin βl ++/+ ++/+ ++
VCAM-1 + + ++
MyoD - - - α-SM actin ++/- ++/- ++/+/■
Neurofilam. - - -
MUC-18 ++/- ++/+/- ++/+/■
Collagen-I + ++ ++/+
Collagen-II - - -
Collagen-III ++/+ ++/+ ++/+
Osteocalcin ++/+ ++/+ +/-
Osteonectin ++/+ ++ ++/+
BSP - - +/-
Osteopontin +/- +/- +/-
Alk Phos ++/+/- ++/+/- ++/+/■
PPARγ - - -
FGF-2 ++/+ ++ ++/+
(++) Strong staining, (+) Weak staining, (-) Negative, (/) Subpopulation
Claims (9)
1. A culture of isolated adult human dental pulp stem cells.
2. The culture of claim 1, wherein the stem cells can differentiate into odontoblasts.
3. The culture of claim 1, wherein the stem cells can regenerate a dentin/pulp structure in vivo.
4. The culture of claim 1, wherein the stem cells are not adipogenic.
5. The culture of claim 1, wherein the cells do not produce bone sialoprotein.
6. A method of regenerating human dentin/pulp tissue, comprising: a) contacting a cell from the culture of claim 1 with a mineral source; and b) transplanting the cell from step a) into a mammal.
7. The method of claim 6, wherein the mineral source is hydroxyapatite/tricalcium phosphate.
8. A method of producing human dentin/pulp tissue, comprising: a) contacting a cell from the culture of claim 1 with a mineral source; and b) transplanting the cell from step a) into a mammal.
9. The method of claim 8, wherein the mineral source is hydroxyapatite/tricalcium phosphate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21998900P | 2000-07-21 | 2000-07-21 | |
| US60/219,989 | 2000-07-21 | ||
| PCT/US2001/023053 WO2002007679A2 (en) | 2000-07-21 | 2001-07-23 | Adult human dental pulp stem cells in vitro and in vivo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001277078A1 true AU2001277078A1 (en) | 2002-05-02 |
| AU2001277078B2 AU2001277078B2 (en) | 2006-04-27 |
Family
ID=22821575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU7707801A Pending AU7707801A (en) | 2000-07-21 | 2001-07-23 | Adult human dental pulp stem cells in vitro and in vivo |
| AU2001277078A Expired AU2001277078B2 (en) | 2000-07-21 | 2001-07-23 | Adult human dental pulp stem cells in vitro and in vivo |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU7707801A Pending AU7707801A (en) | 2000-07-21 | 2001-07-23 | Adult human dental pulp stem cells in vitro and in vivo |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7052907B2 (en) |
| EP (1) | EP1305400B1 (en) |
| JP (3) | JP5645338B2 (en) |
| AU (2) | AU7707801A (en) |
| CA (1) | CA2416801C (en) |
| ES (1) | ES2423898T3 (en) |
| WO (1) | WO2002007679A2 (en) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100203481A1 (en) * | 1996-03-21 | 2010-08-12 | Nova Southeastern University | Method and kit for delivering endodontic regenerative treatment |
| AUPQ147799A0 (en) | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
| US8062675B2 (en) | 1999-07-07 | 2011-11-22 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
| US7670628B2 (en) | 1999-07-07 | 2010-03-02 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
| AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| EP1456357B1 (en) | 2002-02-06 | 2008-06-04 | Stiftung CAESAR | Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| US20060076295A1 (en) | 2004-03-15 | 2006-04-13 | The Trustees Of Columbia University In The City Of New York | Systems and methods of blood-based therapies having a microfluidic membraneless exchange device |
| ATE510605T1 (en) | 2003-03-14 | 2011-06-15 | Univ Columbia | SYSTEMS AND METHODS FOR BLOOD BASED THERAPY USING A MEMBRANELESS MICROFLUID EXCHANGE DEVICE |
| WO2004094588A2 (en) * | 2003-04-19 | 2004-11-04 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Postnatal stem cells and uses thereof |
| US7309232B2 (en) * | 2003-10-10 | 2007-12-18 | Dentigenix Inc. | Methods for treating dental conditions using tissue scaffolds |
| BRPI0402659A (en) * | 2004-06-23 | 2006-01-31 | Univ Fed Sao Paulo Unifesp | Stem cell use, tissue engineering method, dental tissue use and biological tooth replacement |
| JP4831687B2 (en) * | 2004-07-23 | 2011-12-07 | 株式会社カネカ | Method for inducing differentiation from mesenchymal stem cells to odontoblasts |
| ITNA20040043A1 (en) * | 2004-07-28 | 2004-10-28 | Francesco Carinci | TECHNIQUE OF TISSUE ENGINEERING OBTAINABLE BY ISOLATION OF A NEW SUBPOPOLATION OF MBP-SHED AND MBP-DPSC STEM CELLS, ISOLATED FROM PULP OF DECIDENT AND PERMANENT TEETH ABLE TO PRODUCE IN VITRO HUMAN BONE TISSUE. |
| TW200609355A (en) * | 2004-09-01 | 2006-03-16 | Tzu Chi Buddhist General Hospital | Nurr1-positive neuron stem cells, pharmaceutical composition thereof and methods for their isolation, culture and preservation |
| AU2005287855B2 (en) | 2004-09-24 | 2011-06-16 | Mesoblast, Inc. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) |
| JP4884678B2 (en) * | 2005-02-03 | 2012-02-29 | 国立大学法人名古屋大学 | Dentin regeneration from human dental pulp cells |
| US20070258957A1 (en) * | 2006-05-04 | 2007-11-08 | Russell Bowermaster | Method for obtaining and storing multipotent stem cells |
| DE602005012081D1 (en) * | 2005-07-29 | 2009-02-12 | Univ Bonn | Method for isolating stem cells from a pillow-shaped tissue of the teeth |
| JP4781037B2 (en) * | 2005-08-01 | 2011-09-28 | 株式会社カネカ | Identification and selection of human dental pulp cells |
| KR100759388B1 (en) | 2005-08-02 | 2007-09-19 | 유형근 | Method of osteoblastic differentiation of alveolar bone marrow-derived adult stem cell |
| EP1952821B1 (en) * | 2005-10-19 | 2013-02-20 | Osaka University | Therapeutic agent for dentin-dental pulp complex regeneration |
| US7448871B2 (en) * | 2005-12-09 | 2008-11-11 | Krasner Paul R | Apparatus and method for storing and transporting teeth |
| ATE542583T1 (en) | 2006-05-22 | 2012-02-15 | Univ Columbia | METHOD FOR MEMBRANE-LESS MICROFLUID EXCHANGE IN AN H-FILTER AND FILTERING OF THE EXTRACTION FLUID OUTPUT STREAMS |
| US10232080B2 (en) * | 2006-11-29 | 2019-03-19 | University Of Southern California | Mesenchymal stem cell-mediated function tooth regeneration |
| CN101668848B (en) | 2007-04-26 | 2014-10-22 | 雷蒙特亚特特拉维夫大学有限公司 | Pluripotent autologous stem cells from oral mucosa and methods of use |
| US8574567B2 (en) * | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| EP2155860B1 (en) | 2007-05-03 | 2014-08-27 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| US20100098670A1 (en) * | 2007-11-21 | 2010-04-22 | Cerapedics Inc. | Autologous dental pulp stem cell-based bone graft substitute |
| US20110002895A1 (en) * | 2007-12-05 | 2011-01-06 | Minoru Ueda | Composition for autotransplantation or allotransplantation using dental pulp stem cell, and use of the composition |
| JP2011505970A (en) * | 2007-12-14 | 2011-03-03 | ノバ サウスイースタン ユニバーシティー | Endodontic treatment and kit for delivering the same |
| CA2709490A1 (en) | 2007-12-19 | 2009-07-09 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| JP2011514182A (en) | 2008-02-04 | 2011-05-06 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Fluid separation apparatus, system, and method |
| US20110236977A1 (en) * | 2008-04-02 | 2011-09-29 | The Trustees Of Columbia University In The City Of New York | Dental stem cell differentiation |
| CA2745760A1 (en) | 2008-12-04 | 2010-06-10 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| WO2010080527A1 (en) | 2008-12-19 | 2010-07-15 | Novozymes, Inc. | Methods for determining cellulolytic enhancing activity of a polypeptide |
| DK2379712T3 (en) | 2008-12-19 | 2017-05-08 | Novozymes Inc | Methods for Increasing Hydrolysis of Cellulosic Material in the Presence of Cellobiose Dehydrogenase |
| CN102325893A (en) | 2008-12-19 | 2012-01-18 | 诺维信股份有限公司 | Methods for increasing enzymatic hydrolysis of cellulosic material in the presence of a peroxidase |
| US10328103B2 (en) | 2009-01-03 | 2019-06-25 | Ray C. Wasielewski | Medical treatment composition comprising mammalian dental pulp stem cells |
| US8470308B2 (en) * | 2009-01-03 | 2013-06-25 | Ray C. Wasielewski | Enhanced medical implant comprising disrupted tooth pulp and tooth particles |
| US8604277B2 (en) | 2009-01-28 | 2013-12-10 | Novozymes, Inc. | Polypeptides having beta-glucosidase activity and polynucleotides encoding same |
| ES2534078T3 (en) | 2009-06-02 | 2015-04-17 | Novozymes Inc. | Polypeptides with cellobiohydrolase activity and polynucleotides encoding them |
| US20120164604A1 (en) * | 2009-09-11 | 2012-06-28 | National Center For Geriatrics And Gerontology | Unextracted tooth root canal filler and dental tissue regeneration method for unextracted tooth |
| WO2011035027A2 (en) | 2009-09-17 | 2011-03-24 | Novozymes, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| ES2560805T3 (en) | 2009-09-29 | 2016-02-22 | Novozymes Inc. | Polypeptides with cellulolytic enhancing activity and polynucleotides that encode them |
| CN102648276A (en) | 2009-09-29 | 2012-08-22 | 诺维信股份有限公司 | Polypeptides having xylanase activity and polynucleotides encoding same |
| EP2977382A3 (en) | 2009-09-30 | 2016-05-11 | Novozymes Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| KR101194821B1 (en) | 2009-10-08 | 2012-10-25 | 경북대학교 산학협력단 | Chelating agent -soluble tooth protein and usage thereof |
| US20120260371A1 (en) | 2009-10-29 | 2012-10-11 | Novozymes A/S | Polypeptides Having Cellobiohydrolase Activity and Polynucleotides Encoding Same |
| EP2496693B1 (en) | 2009-11-06 | 2017-10-25 | Novozymes, Inc. | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same |
| CN102639697B (en) | 2009-11-06 | 2015-03-25 | 诺维信股份有限公司 | Polypeptides having xylanase activity and polynucleotides encoding same |
| WO2011069093A1 (en) | 2009-12-04 | 2011-06-09 | Boston Biomedical Research Institute, Inc. | Detecting and counting tissue-specific stem cells and uses thereof |
| US8759098B2 (en) | 2009-12-04 | 2014-06-24 | Boston Biomedical Research Institute, Inc. | Method for cloning pluripotent stem cells |
| US8828701B2 (en) | 2010-03-31 | 2014-09-09 | Novozymes, Inc. | Cellobiohydrolase variants and polynucleotides encoding same |
| US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| DK2588604T3 (en) | 2010-06-30 | 2016-09-26 | Novozymes Inc | Polypeptides having beta-glucosidase activity and polynucleotides encoding them |
| DK2670853T3 (en) | 2011-01-31 | 2017-08-28 | Novozymes North America Inc | Process for enzymatic refining of pretreated cellulosic material for sugars |
| US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
| RU2466680C1 (en) * | 2011-10-03 | 2012-11-20 | Общество С Ограниченной Ответственностью "Витацел" | Diagnostic technique for patient's skin conditions |
| EP2633870B1 (en) * | 2012-02-29 | 2018-08-01 | Technische Universität Berlin | Method of preparing an artificial tooth primordium in vitro and artificial tooth primordium derived therefrom |
| WO2013146992A1 (en) | 2012-03-29 | 2013-10-03 | 日本ケミカルリサーチ株式会社 | Method for producing pluripotent stem cells derived from dental pulp |
| US9790468B2 (en) | 2013-03-15 | 2017-10-17 | Avita Iinternational Ltd. | Multifunctional immature dental pulp stem cells and therapeutic applications |
| CA2986702C (en) | 2015-05-21 | 2023-04-04 | David Wang | Modified demineralized cortical bone fibers |
| CA3103769A1 (en) | 2018-07-31 | 2020-02-06 | Jcr Pharmaceuticals Co., Ltd. | Method for producing dental pulp-derived cells |
| CA3146004A1 (en) * | 2019-07-29 | 2021-02-04 | Relevance Total Health | Compositions and methods of using multipotent stem cells to reduce disease and enhance wellness |
| US20230086254A1 (en) | 2020-01-30 | 2023-03-23 | Jcr Pharmaceuticals Co., Ltd. | Medicinal composition comprising dental pulp-derived cells |
| WO2023227972A1 (en) | 2022-05-24 | 2023-11-30 | Iceta - Instituto De Ciências, Tecnologias E Agroambiente Da Universidade Do Porto | Process for preparation and cryopreservation of dental pulp from definitive teeth and products thereof based on isolated mesenchymal stem cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0915967A1 (en) * | 1996-05-28 | 1999-05-19 | The Board Of Regents Of The University Of Michigan | Engineering oral tissues |
| US6328765B1 (en) * | 1998-12-03 | 2001-12-11 | Gore Enterprise Holdings, Inc. | Methods and articles for regenerating living tissue |
| US7670628B2 (en) * | 1999-07-07 | 2010-03-02 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
| US6899915B2 (en) * | 2000-11-29 | 2005-05-31 | President And Fellows Of Harvard College | Methods and compositions for culturing a biological tooth |
| US6767740B2 (en) * | 2001-10-09 | 2004-07-27 | Roger Anton Sramek | Stem cell and dental pulp harvesting method and apparatus |
| FR2833610B1 (en) * | 2001-12-14 | 2007-01-26 | Natural Implant | IN VITRO CULTIVE CELL CONSTRUCTS, PREPARATION AND USES |
| EP1456357B1 (en) * | 2002-02-06 | 2008-06-04 | Stiftung CAESAR | Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| US7309232B2 (en) * | 2003-10-10 | 2007-12-18 | Dentigenix Inc. | Methods for treating dental conditions using tissue scaffolds |
-
2001
- 2001-07-23 CA CA2416801A patent/CA2416801C/en not_active Expired - Lifetime
- 2001-07-23 US US10/333,522 patent/US7052907B2/en not_active Expired - Lifetime
- 2001-07-23 ES ES01954858T patent/ES2423898T3/en not_active Expired - Lifetime
- 2001-07-23 AU AU7707801A patent/AU7707801A/en active Pending
- 2001-07-23 JP JP2002513417A patent/JP5645338B2/en not_active Expired - Lifetime
- 2001-07-23 WO PCT/US2001/023053 patent/WO2002007679A2/en active Application Filing
- 2001-07-23 EP EP01954858.5A patent/EP1305400B1/en not_active Expired - Lifetime
- 2001-07-23 AU AU2001277078A patent/AU2001277078B2/en not_active Expired
-
2012
- 2012-04-27 JP JP2012103397A patent/JP5635556B2/en not_active Expired - Lifetime
-
2014
- 2014-09-09 JP JP2014183191A patent/JP5976740B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2416801C (en) | Adult human dental pulp stem cells in vitro and in vivo | |
| AU2001277078A1 (en) | Adult human dental pulp stem cells in vitro and in vivo | |
| AU2003231015B2 (en) | Postnatal stem cells and uses thereof | |
| CA2459202C (en) | Adipose-derived stem cells and lattices | |
| US20150376572A1 (en) | Adipose-derived stem cells and lattices | |
| US20050153442A1 (en) | Adipose-derived stem cells and lattices | |
| EP1934332B1 (en) | Methods for differentiating stem cells and use thereof in the treatment of dental conditions | |
| CA2809164C (en) | Postnatal stem cells and uses thereof | |
| Liu et al. | Dental pulp stem cells | |
| Xiong | Isolation and charaterization of stem cell populations in the periodontium. |